Pulido Ortega, Federico
Switching to lopinavir/ritonavir with or without abacavir/lamivudine in lipoatrophic patients treated with zidovudine/abacavir/lamivudine. [artículo] - The Journal of antimicrobial chemotherapy, 2013 - 68(6):1373-81.
Formato Vancouver:
Bernardino JI, Pulido F, Martínez E, Arrizabalaga J, Domingo P, Portilla J et al. GESIDA-6008-KRETA Study Group. Switching
to lopinavir/ritonavir with or without abacavir/lamivudine in lipoatrophic patients treated with zidovudine/abacavir/lamivudine. J Antimicrob Chemother. 2013 Jun;68(6):1373-81.
PMID: 23386261
Contiene 31 referencias
BACKGROUND: Discontinuation of thymidine nucleoside reverse transcriptase inhibitors (tNRTIs) is the only proven strategy for improving lipoatrophy. It is unclear whether switching to NRTI-sparing or to non-thymidine NRTI-containing therapy has differential effects on body fat recovery.
Switching to lopinavir/ritonavir with or without abacavir/lamivudine in lipoatrophic patients treated with zidovudine/abacavir/lamivudine. [artículo] - The Journal of antimicrobial chemotherapy, 2013 - 68(6):1373-81.
Formato Vancouver:
Bernardino JI, Pulido F, Martínez E, Arrizabalaga J, Domingo P, Portilla J et al. GESIDA-6008-KRETA Study Group. Switching
to lopinavir/ritonavir with or without abacavir/lamivudine in lipoatrophic patients treated with zidovudine/abacavir/lamivudine. J Antimicrob Chemother. 2013 Jun;68(6):1373-81.
PMID: 23386261
Contiene 31 referencias
BACKGROUND: Discontinuation of thymidine nucleoside reverse transcriptase inhibitors (tNRTIs) is the only proven strategy for improving lipoatrophy. It is unclear whether switching to NRTI-sparing or to non-thymidine NRTI-containing therapy has differential effects on body fat recovery.
